Blood test for can­cer de­tec­tion com­pa­ny Grail rakes in $390M in lat­est round

Just over a week af­ter Third Rock-backed Thrive un­veiled ‘re­al world’ da­ta from a large study eval­u­at­ing the abil­i­ty of its blood test to sniff out ear­ly signs of can­cer in in­di­vid­u­als with no his­to­ry of the dis­ease, ri­val Grail has raised a gar­gan­tu­an $390 mil­lion in its lat­est round of fi­nanc­ing.

Grail — which was carved out of the DNA se­quenc­ing com­pa­ny Il­lu­mi­na in 2016 — has a mul­ti-can­cer de­tec­tion blood test that re­lies on DNA se­quenc­ing to as­sess methy­la­tion, an epi­ge­net­ic change across the genome to ex­pose can­cer sig­nals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER